دورية أكاديمية
أعرض في EDS

An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam.

التفاصيل البيبلوغرافية
العنوان: An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam.
المؤلفون: Chau NVV; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Ngoc NM; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Nguyet LA; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam., Quang VM; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Ny NTH; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam., Khoa DB; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Phong NT; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Toan LM; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Hong NTT; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam., Tuyen NTK; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam., Phat VV; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam., Nhu LNT; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam., Truc NHT; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., That BTT; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Thao HP; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Thao TNP; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Vuong VT; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Tam TTT; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Tai NT; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Bao HT; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Nhung HTK; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Minh NTN; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Tien NTM; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Huy NC; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Choisy M; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Man DNH; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Ty DTB; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Anh NT; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam., Uyen LTT; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Tu TNH; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Yen LM; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam., Dung NT; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Hung LM; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Truong NT; Hospital for Tropical Diseaes, Ho Chi Minh City, Vietnam., Thanh TT; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam., Thwaites G; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Tan LV; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
المصدر: EClinicalMedicine [EClinicalMedicine] 2021 Nov; Vol. 41, pp. 101143. Date of Electronic Publication: 2021 Sep 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: The Lancet Country of Publication: England NLM ID: 101733727 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2589-5370 (Electronic) Linking ISSN: 25895370 NLM ISO Abbreviation: EClinicalMedicine Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [London] : The Lancet, [2018]-
مستخلص: Background: Data on breakthrough SARS-CoV-2 Delta variant infections in vaccinated individuals are limited.
Methods: We studied breakthrough infections among Oxford-AstraZeneca vaccinated healthcare workers in an infectious diseases hospital in Vietnam. We collected demographic and clinical data alongside serial PCR testing, measurement of SARS-CoV-2 antibodies, and viral whole-genome sequencing.
Findings: Between 11 th -25 th June 2021 (7-8 weeks after the second dose), 69 staff tested positive for SARS-CoV-2. 62 participated in the study. Most were asymptomatic or mildly symptomatic and all recovered. Twenty-two complete-genome sequences were obtained; all were Delta variant and were phylogenetically distinct from contemporary viruses obtained from the community or from hospital patients admitted prior to the outbreak. Viral loads inferred from Ct values were 251 times higher than in cases infected with the original strain in March/April 2020. Median time from diagnosis to negative PCR was 21 days (range 8-33). Neutralizing antibodies (expressed as percentage of inhibition) measured after the second vaccine dose, or at diagnosis, were lower in cases than in uninfected, fully vaccinated controls (median (IQR): 69.4 (50.7-89.1) vs. 91.3 (79.6-94.9), p=0.005 and 59.4 (32.5-73.1) vs. 91.1 (77.3-94.2), p=0.002). There was no correlation between vaccine-induced neutralizing antibody levels and peak viral loads or the development of symptoms.
Interpretation: Breakthrough Delta variant infections following Oxford-AstraZeneca vaccination may cause asymptomatic or mild disease, but are associated with high viral loads, prolonged PCR positivity and low levels of vaccine-induced neutralizing antibodies. Epidemiological and sequence data suggested ongoing transmission had occurred between fully vaccinated individuals.
Funding: Wellcome and NIH/NIAID.
Competing Interests: All authors declare no competing interests.
(© 2021 The Author(s).)
References: Lancet. 2021 Jun 19;397(10292):2331-2333. (PMID: 34090624)
Nat Commun. 2021 Jan 11;12(1):267. (PMID: 33431879)
Euro Surveill. 2020 Jan;25(3):. (PMID: 31992387)
Clin Infect Dis. 2020 Dec 17;71(10):2679-2687. (PMID: 32497212)
Nat Commun. 2022 Jan 24;13(1):460. (PMID: 35075154)
Nat Biotechnol. 2020 Sep;38(9):1073-1078. (PMID: 32704169)
Clin Infect Dis. 2022 Apr 9;74(7):1275-1278. (PMID: 34363462)
N Engl J Med. 2021 Dec 16;385(25):e92. (PMID: 34758250)
Cell. 2021 Apr 29;184(9):2348-2361.e6. (PMID: 33730597)
Science. 2021 Jul 9;373(6551):. (PMID: 34035154)
Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089)
N Engl J Med. 2021 Aug 12;385(7):585-594. (PMID: 34289274)
N Engl J Med. 2021 Oct 14;385(16):1474-1484. (PMID: 34320281)
Nat Immunol. 2021 Mar;22(3):261. (PMID: 33627879)
BMC Med. 2021 Oct 1;19(1):255. (PMID: 34593004)
N Engl J Med. 2021 Sep 9;385(11):1051-1052. (PMID: 34233109)
Nat Microbiol. 2020 Nov;5(11):1403-1407. (PMID: 32669681)
J Infect. 2021 Jan;82(1):e36-e37. (PMID: 33221367)
Am J Trop Med Hyg. 2022 Jan 07;106(2):556-561. (PMID: 34996048)
Mol Biol Evol. 2015 Jan;32(1):268-74. (PMID: 25371430)
MMWR Morb Mortal Wkly Rep. 2021 Aug 06;70(31):1059-1062. (PMID: 34351882)
معلومات مُعتمدة: 204904/Z/16/Z United Kingdom WT_ Wellcome Trust
فهرسة مساهمة: Keywords: COVID-19; Delta variant; Oxford-AstraZeneca; Vietnam; vaccine breakthrough
تواريخ الأحداث: Date Created: 20211005 Latest Revision: 20231107
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8481205
DOI: 10.1016/j.eclinm.2021.101143
PMID: 34608454
قاعدة البيانات: MEDLINE
الوصف
تدمد:2589-5370
DOI:10.1016/j.eclinm.2021.101143